Mechanism of action
L-Tryptophan is an essential aromatic amino acid that cannot be synthesized de novo in humans and must be obtained through diet. After absorption, tryptophan crosses the blood-brain barrier via the large neutral amino acid transporter (LAT1) and undergoes enzymatic conversion in the central nervous system.
The primary pathway involves hydroxylation by tryptophan hydroxylase (the rate-limiting step) to form 5-hydroxytryptophan (5-HTP), which is then rapidly decarboxylated by aromatic L-amino acid decarboxylase to produce serotonin (5-hydroxytryptamine, 5-HT). Serotonin functions as a key neurotransmitter regulating mood, sleep, appetite, and pain perception. Serotonin can be further converted to melatonin in the pineal gland, explaining tryptophan's sleep-promoting effects.
An alternative metabolic pathway (the kynurenine pathway) converts tryptophan to niacin (vitamin B3) via kynurenine and quinolinic acid. This pathway accounts for approximately 95% of dietary tryptophan metabolism in peripheral tissues. Supplementation aims to increase serotonin synthesis by providing excess substrate to overcome competitive inhibition at the LAT1 transporter.
- L-Tryptophan is the dietary precursor to serotonin, melatonin, and niacin (vitamin B3).
- The rate-limiting step in serotonin synthesis is tryptophan hydroxylase converting tryptophan to 5-HTP.
- Eosinophilia-myalgia syndrome (EMS) outbreak in 1989 was caused by contaminated tryptophan supplements, not the amino acid itself.
- Tryptophan competes with other large neutral amino acids (leucine, isoleucine, valine) for blood-brain barrier transport via LAT1.
- Combining tryptophan with SSRIs, MAOIs, or other serotonergic agents significantly increases serotonin syndrome risk.
- Carbohydrate co-administration enhances tryptophan brain uptake by reducing competing amino acid levels via insulin-mediated muscle uptake.
- Most dietary tryptophan (95%) is metabolized via the kynurenine pathway to niacin, not serotonin.
- Acute tryptophan depletion (ATD) is a research method that temporarily lowers brain serotonin and can precipitate depression in vulnerable individuals.
Indications
L-Tryptophan is used as a dietary supplement and adjunctive treatment for several psychiatric and sleep disorders:
- Depression: Used as adjunctive therapy in major depressive disorder, particularly when conventional antidepressants provide partial response
- Insomnia: Promotes sleep onset and improves sleep quality by increasing serotonin and melatonin synthesis
- Premenstrual dysphoric disorder (PMDD): May reduce mood and behavioral symptoms
- Seasonal affective disorder: Adjunctive treatment during winter months
- Obsessive-compulsive symptoms: Limited evidence for mild OCD symptoms
Tryptophan is also found naturally in protein-rich foods (turkey, chicken, milk, eggs, nuts) and is sometimes used in functional foods. In many jurisdictions, it is regulated as a dietary supplement rather than a prescription medication. Clinical evidence supporting its efficacy is moderate, with better-established alternatives (SSRIs, SNRIs) typically preferred as first-line treatments.
Pharmacokinetics
Absorption: Rapidly absorbed from the small intestine following oral administration. Absorption competes with other large neutral amino acids (leucine, isoleucine, valine, tyrosine, phenylalanine), so high-protein meals may reduce bioavailability. Peak plasma levels occur 1-2 hours after ingestion.
Distribution: Crosses the blood-brain barrier via LAT1, a saturable transport system. Competition from other amino acids influences CNS penetration. Approximately 80-90% of circulating tryptophan is bound to albumin.
Metabolism: Undergoes hepatic metabolism primarily via the kynurenine pathway (95%) to produce niacin metabolites and quinolinic acid. A smaller fraction (1-2%) is converted to serotonin in the brain and peripheral tissues. Metabolism can be influenced by inflammatory states, which upregulate indoleamine 2,3-dioxygenase (IDO) and shift metabolism away from serotonin synthesis.
Elimination: Metabolites are excreted renally. The elimination half-life of tryptophan itself is relatively short (2-3 hours), but downstream effects on serotonin synthesis persist longer.
Adverse effects
Eosinophilia-myalgia syndrome (EMS): The most historically significant adverse effect occurred in 1989 when contaminated L-tryptophan supplements caused an outbreak of EMS, characterized by severe myalgia, eosinophilia (>1000 cells/μL), skin changes, and potentially fatal multi-organ involvement. The contaminant was traced to a manufacturing process at a single Japanese company. Modern pharmaceutical-grade tryptophan is considered safe, but this event led to temporary market withdrawal in many countries.
Serotonin syndrome: Risk is elevated when tryptophan is combined with other serotonergic agents (SSRIs, SNRIs, MAOIs, tramadol, linezolid). Symptoms include hyperthermia, rigidity, myoclonus, altered mental status, autonomic instability, and hyperreflexia.
Common adverse effects:
- Gastrointestinal: Nausea, anorexia, dry mouth
- Neurological: Drowsiness, dizziness, headache, lightheadedness
- Sexual dysfunction (less common than with SSRIs)
- Blurred vision
Rare but serious:
- Hepatotoxicity (rare case reports)
- Worsening of psychosis in schizophrenia patients
- Activation of mania in bipolar disorder
Contraindications and warnings
Absolute contraindications:
- Hypersensitivity to L-tryptophan or any formulation component
- Concurrent use with MAOIs or within 14 days of MAOI discontinuation (serotonin syndrome risk)
- Active eosinophilia-myalgia syndrome
Relative contraindications and warnings:
- Pregnancy and lactation: Limited safety data; generally avoided unless benefits outweigh risks (Pregnancy Category C equivalent)
- Renal or hepatic impairment: Dose adjustment may be necessary; metabolite accumulation possible
- Schizophrenia or psychotic disorders: May exacerbate symptoms
- Bipolar disorder: Risk of precipitating manic episodes
- Bladder cancer: Some animal studies suggested increased risk with high-dose tryptophan metabolites (controversial)
Monitoring: Patients should be monitored for signs of serotonin syndrome when initiating therapy or combining with other serotonergic drugs. Baseline and periodic complete blood counts may be considered given the historical EMS association, though modern products carry minimal risk.
Carcinoid syndrome: Tryptophan supplementation is contraindicated in carcinoid tumors, which already produce excess serotonin.
Drug interactions
Serotonergic agents (major interaction):
- SSRIs (fluoxetine, sertraline, paroxetine, citalopram)
- SNRIs (venlafaxine, duloxetine)
- MAOIs (phenelzine, tranylcypromine, selegiline)
- Tricyclic antidepressants
- Tramadol, meperidine, fentanyl
- Linezolid (antibiotic with MAOI activity)
- St. John's wort
- 5-HTP supplements
- Triptans (sumatriptan, rizatriptan)
Combined use increases serotonin syndrome risk. If combination is necessary, start with low doses and monitor closely.
CNS depressants: Additive sedative effects with benzodiazepines, alcohol, barbiturates, antihistamines, and opioids.
Competitive amino acids: High-protein meals or supplements containing leucine, isoleucine, valine, tyrosine, or phenylalanine reduce tryptophan absorption and brain uptake via competition at LAT1.
Carbidopa and levodopa: May alter tryptophan metabolism and reduce efficacy.
Immunosuppressants: Drugs affecting the kynurenine pathway (glucocorticoids, IFN-gamma) may alter tryptophan metabolism away from serotonin synthesis.
Clinical pearls
- Tryptophan vs 5-HTP: 5-HTP crosses the blood-brain barrier more readily because it bypasses the rate-limiting tryptophan hydroxylase step and does not compete with other amino acids at LAT1. However, 5-HTP carries higher serotonin syndrome risk.
- Dietary context: The traditional notion that turkey causes drowsiness due to tryptophan is overstated. Turkey contains similar tryptophan levels to other poultry, and post-meal sleepiness is more attributable to carbohydrate-induced insulin release, which reduces competing amino acids and favors tryptophan brain uptake.
- Carbohydrate co-administration: Consuming tryptophan with carbohydrates (without protein) enhances brain uptake because insulin drives competing amino acids into muscle, reducing LAT1 competition.
- Psychiatric consultation: Tryptophan should not replace first-line psychiatric treatments. It may serve as adjunctive therapy in treatment-resistant cases under medical supervision.
- Quality concerns: Given the EMS outbreak, only pharmaceutical-grade or rigorously tested supplements should be used. Contamination remains a theoretical risk with poorly manufactured products.
- Tryptophan depletion studies: Acute tryptophan depletion (ATD) is a research technique used to study serotonin's role in mood disorders. Subjects consume amino acid mixtures lacking tryptophan, temporarily reducing brain serotonin synthesis and sometimes precipitating depressive symptoms in vulnerable individuals.
- Nicotinic acid synthesis: Approximately 60 mg of dietary tryptophan yields 1 mg niacin equivalent, making tryptophan important for preventing pellagra (niacin deficiency) in diets low in both nutrients.
TRYPTophan pathway: Tryptophan → Rate-limiting trYptophan hydroxylase → P (5-HTP) → Serotonin → Melatonin (in pineal gland).
Practice questions
1. A 35-year-old woman with major depressive disorder on fluoxetine daily reports persistent insomnia despite treatment. She begins taking L-tryptophan supplements nightly. Three days later, she presents to the emergency department with agitation, diaphoresis, tremor, hyperreflexia, and a temperature of 39.2°C (102.6°F). Which of the following best explains her presentation?
2. A researcher designs a study to investigate serotonin's role in mood regulation. Healthy volunteers consume an amino acid mixture containing leucine, isoleucine, valine, phenylalanine, and tyrosine, but no tryptophan. Six hours later, subjects with a family history of depression report mild dysphoric symptoms. Which of the following best explains this finding?
3. A 28-year-old man is brought to the emergency department after being found unconscious. History reveals he was recently started on phenelzine for atypical depression and began taking L-tryptophan supplements for insomnia. On examination, he is febrile, rigid, and has sustained clonus. Which of the following medication combinations would pose the highest risk for this patient's condition?
Frequently asked questions
How does L-tryptophan work?
L-Tryptophan works by serving as the precursor to serotonin (5-HT) synthesis in the brain. After crossing the blood-brain barrier, it is converted by tryptophan hydroxylase to 5-hydroxytryptophan (5-HTP), which is then decarboxylated to serotonin. Increased serotonin levels improve mood, promote sleep, and regulate appetite. Serotonin can be further converted to melatonin in the pineal gland, enhancing sleep-wake cycle regulation.
What are the side effects of L-tryptophan?
Common side effects include nausea, drowsiness, dizziness, dry mouth, and headache. The most serious historical adverse effect is eosinophilia-myalgia syndrome (EMS), which occurred in 1989 due to contaminated supplements and caused severe muscle pain, high eosinophil counts, and multi-organ damage. Modern pharmaceutical-grade tryptophan is considered safe. When combined with other serotonergic drugs (SSRIs, MAOIs), tryptophan can cause serotonin syndrome, a potentially life-threatening condition with symptoms including hyperthermia, rigidity, and altered mental status.
Is L-tryptophan a controlled substance?
No, L-tryptophan is not a controlled substance in most jurisdictions. It is classified as a dietary supplement or amino acid product rather than a prescription medication in the United States and many other countries. However, following the 1989 EMS outbreak, some countries temporarily banned or restricted its sale. Currently, pharmaceutical-grade tryptophan is widely available over-the-counter, though regulations vary by country regarding labeling, purity standards, and approved health claims.
L-tryptophan vs 5-HTP — what is the difference?
L-Tryptophan and 5-HTP (5-hydroxytryptophan) are both serotonin precursors, but 5-HTP is one metabolic step closer to serotonin. 5-HTP crosses the blood-brain barrier more efficiently because it doesn't compete with other amino acids at the LAT1 transporter and bypasses the rate-limiting tryptophan hydroxylase enzyme. This makes 5-HTP more potent but also carries higher risk of serotonin syndrome, especially with concurrent serotonergic medications. Tryptophan has a broader safety margin and undergoes more metabolic regulation.
Can L-tryptophan help with sleep and insomnia?
Yes, L-tryptophan can improve sleep quality and reduce sleep onset latency in some individuals. Its mechanism involves conversion to serotonin, which is then converted to melatonin in the pineal gland, promoting natural sleep-wake cycle regulation. Clinical evidence shows modest benefit for mild insomnia, though effects are generally less pronounced than prescription sleep medications. Taking tryptophan 30-60 minutes before bedtime with a carbohydrate-containing snack may enhance effectiveness by improving brain uptake.
Conditions it is used for
Related drugs
Sources and further reading
DailyMed (FDA labels)StatPearls (NCBI Bookshelf)MedlinePlusWHO ATC/DDD index: N06AX02
Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.